Trial Profile
PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 15 Jun 2023
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Fludarabine (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
- Focus Therapeutic Use
- Acronyms FLUBUTBI
- 09 Jun 2023 Status changed from active, no longer recruiting to discontinued.
- 18 Nov 2022 Planned End Date changed from 1 Aug 2023 to 1 May 2023.
- 25 Feb 2022 Planned End Date changed from 1 Aug 2022 to 1 Aug 2023.